Headquartered in Biberach an der Riß, Germany, SENSIFIC develops and delivers next-generation, image-activated cell sorters (IACS) and high-performance camera systems that power breakthrough discoveries in science and industry. SENSIFIC systems enable high-resolution analysis and sorting of cells, droplets, spheroids, and particles. The company’s technologies are driving progress in drug discovery, personalized medicine, organoid screening, and beyond – supporting critical applications like cancer therapy, virology, Alzheimer’s research, and microbial studies.
Interview with Dr. Kirsten Geiger, Managing Director at SENSIFIC.
What are the main areas of activity of the company?
Kirsten Geiger: The vision at SENSIFIC is to redefine the future of cell sorting and imaging technology. Our innovative solutions combine droplet- and flow-based sorting with precision microfluidics, advanced imaging, and intelligent data processing. From microfluidic chips to intuitive software, we offer a complete ecosystem designed to accelerate research and streamline workflows.
What’s the news about new products/services?
K.G: In late 2025, we introduced two advanced platforms for droplet microfluidics and cell analysis. DropletONE is an all-in-one system that combines droplet generation, high-speed imaging, and label-free sorting in a compact design with integrated software and feedback control. The IACS eXplorer system is a fully automated Imaging-Fluorescence-Activated Cell Sorter utilizing our established ODIN sensor technology. It enables simultaneous bright-field and fluorescence analysis across four channels for complex assays, including cell therapy applications. These solutions complement our portfolio and address customer demand for fully integrated systems.
What are the ranges of products/services?
K.G: SENSIFIC offers a range of products from modular components to fully integrated systems. Besides the devices we also offer microfluidic chips and custom service like application support or integration of one of our sensors into a customer setup or product. Our aim is to deliver fully working solutions to our customers to support their workflow best. At SENSIFIC, we are more than a technology provider, we are a partner in innovation. Our mission is to empower our customers with tools that deliver unmatched precision, efficiency, and reproducibility, turning complex challenges into game changers.
What is the state of the market where you are currently active?
K.G: SENSIFIC operates in the rapidly growing microfluidics and image-based cell sorting market, currently a niche within the broader Life Sciences sector. Our primary focus is on applications in cell therapy, where precise, label-free and gentle cell analysis that focuses on functional behavior instead of structural parameters is essential for developing innovative treatments. The market is characterized by strong growth potential, driven by increasing demand for high-throughput and modification-free analysis in pharmaceutical research, diagnostics, and advanced therapies. Europe and North America currently lead the market, with Asia-Pacific showing rapid growth. SENSIFIC has established a global presence through strategic partnerships with distributors in the United States, Canada, Mexico, China, and Australia.
What can you tell us about market trends?
K.G: The global cell therapy market is forecasted to more than double by 2030, supported by breakthroughs in immuno-oncology and regenerative medicine. This market is undergoing rapid transformation, driven by demographic changes such as aging populations and the rising incidence of cancer. These factors are fueling demand for advanced solutions in cell analysis and personalized treatments. Personalized medicine is one of the fastest-growing segments, projected to exceed $1 trillion within the next decade, as precision diagnostics, genomics, and AI-based approaches become mainstream. Additionally, microfluidics is emerging as a key enabling technology, with strong growth expected due to its ability to deliver high-throughput, cost-efficient, and miniaturized workflows. Droplet-based systems, in particular, are gaining traction for complex assays and single-cell analysis, which are critical for next-generation therapies. These trends point toward a clear direction: the future of medicine lies in advanced, integrated solutions that combine smart technology with robust assay development to enable truly personalized treatments. To achieve this, collaboration between technology providers, clinics, and research institutions is essential, ensuring that both the tools and the workflows evolve together to meet clinical and industrial demands.
What are the most innovative products/services marketed?
K.G: SENSIFIC’s innovation lies in the sophisticated integration of imaging and fluorescence data, enabling the execution of highly complex assays. To achieve this, we leverage droplet microfluidics to create microreaction vessels where functional reactions can be established by adding reagents directly into droplets. One of the most prominent applications of our technology is the isolation of high-performing cells, for example, selecting highly potent immune cells such as NK or CAR-T cells for personalized treatment. In these assays, modification-free immune cells can be combined with fluorescence-labeled cancer cells within a single microreaction chamber to observe the killing process and to isolate the most effective immune cells. This is only possible because SENSIFIC systems can simultaneously analyze and sort based on imaging and fluorescence data, combined with a built-in droplet generation and sorting system. Our flagship product, ODIN, has already demonstrated proven success in these applications, and we recently complemented it with our fully integrated solution, the IACS eXplorer.
What estimations do you have for the end of 2025?
K.G: With our recently launched two major platforms, DropletONE and IACS eXplorer, we expect to significantly expand our reach into more industry-focused applications. In recent years, SENSIFIC primarily supported research institutes with their workflows. Now, with fully integrated solutions, we can meet the demanding requirements of industrial customers much more effectively. This opens substantial opportunities, particularly in the biotech sector, but also in areas such as the food industry. These steps are crucial for increasing visibility among potential users in these segments and form part of our broader roadmap to support pharmaceutical companies in developing personalized treatments for clinical use. Our goal for the coming years is to provide GMP-compliant and AI-supported systems and further expand our portfolio of measurement technologies that enable smart, label-free cell analysis and sorting.
Sensific GmbH
Hubertus-Liebrecht-Straße 39, 88400 Biberach a. d. Riß, Germany
